About | Free Trial

Last Update

2016-04-23T00:00:00.000Z

This profile was last updated on // .

Is this you? Claim your profile.

Wrong David Buswell?

Mr. David Buswell

Chief Executive Officer

Immune Response BioPharma Inc

Direct Phone: (609) ***-****       

Immune Response BioPharma Inc

2711 Centerville Road Suite 400

Wilmington, Delaware 19808

United States

Company Description

Immune Response BioPharma, Inc. TM is a Delaware corporation and is a leading vaccine development company that has its own proprietary drug pipeline under development and currently owns 100% of its drugs and vaccine treatments. Development of current dr ... more

Background Information

Employment History

Chief Executive Officer and Chief Financial Officer and Chief Operating Officer
The Immune Response Corporation

Not Applicable
none not applicable

Education

Bachelor’s degree
Business & Commerce
University of Mary Washington

Masters Degree

Master’s degree MA
Management & Leadership
Liberty University

Web References (14 Total References)


Executive Team

www.immuneresponsebiopharma.com [cached]

Chief Operating Officer & Chief Financial Officer & CEO: Mr. David Buswell

Mr. David Buswell is founder of Immune Response BioPharma, and is Chief Operating Officer, CFO, President & acting CEO and is Chairman of the Board of Directors. Mr. Buswell holds a Bachelor’s degree in Business & Commerce from the University of Mary Washington, and a Master’s degree MA in Management & Leadership from Liberty University.


Orphan designation will allow for a ...

www.valuebasedrheumatology.com [cached]

Orphan designation will allow for a more speedy development of RAVAX and will give us further flexibility in trial design and expand the RA vaccine use into the rare disease, JRA [juvenile RA], said David Buswell, Chief Operating Officer and Interim Chief Executive Officer of Immune Response BioPharma.


In the Pipeline:

pipeline.corante.com [cached]

Update: Immune Response Biopharma CEO David Buswell has left a detailed comment to this point, pointing out that it was his company that ended talks with GSK, and not the other way around. See here for the details.

...
GSK has no approved MS drug and probably will never have one they are busy wasting their shareholders money on HGSI and a Lupus drug with poor sales, we don't need them or to give away our blockbuster drug for MS to them which we believe will become treatment of choice" IRBP CEO Mr. Buswell
"IRBP values NeuroVax north of a billion dollar of annual sales once approved. We will find a solid partner or raise capital on our own, we don't need GSK which has zer0 experience in multiple sclerosis or auto-immune diseases. GSK is a joke and seems very ignorant on how multiple sclerosis drugs work and how to develop one, we gave them a chance to develop NeuroVax but their management appears to be very poor. We have decided to terminate any collaboration or development with GSK. GSK is a loser in the MS market and will continue to be a loser" IRBP CEO Mr. Buswell
Y'know, in his way, this CEO is a breath of fresh air. Everyone thinks these things in such situations, but not many people put them out on the PR wires. This release seems to have transcribed directly from Mr. Buswell's (no doubt heated) statements at the time, which I'm sure accounts for the take-a-breath grammar.


David Buswell, the chief ...

www.napc.co.uk [cached]

David Buswell, the chief executive of Immune Response Biopharma, has let rip at GlaxoSmithKline in the wake of an apparently acrimonious breakdown in talks over a tie-up involving a multiple sclerosis drug.

Mr Buswell accused GSK's Sir Andrew Witty of 'wasting money' on a £2.6 billion takeover bid for Human Genome Sciences and of devoting resources to the newly approve Benlysta, 'a lupus drug with poor sales'.


"This recent issuance of U.S. 8,053,197 ...

www.healthcareprnews.com [cached]

"This recent issuance of U.S. 8,053,197 is a key patent in that it extends key IP coverage including FOXP3+ Expression Technology related to the delivery and composition of NeuroVax with TCR peptide vaccines including the addition of estrogen to boost the vaccine potential in women suffering from MS." said Mr. David Buswell, IRBP Chief Executive Officer.

...
David Buswell Immune Response BioPharma, Inc. CEO 244 5th avenue suite 1727

Similar Profiles

Other People with this Name

Other people with the name Buswell

Danny Buswell
Comfort Systems USA - South Central

Caleb Buswell
NovaRad Corporation

Angela Buswell
C.H. Robinson Worldwide , Inc.

Laurie Buswell
Salem Audubon Society

Judy Buswell
National Compliance Services Inc

Browse ZoomInfo's Business Contact Directory by City

Browse ZoomInfo's
Business People Directory

Browse ZoomInfo's
Advanced Company Directory